These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28956330)

  • 21. Phosphodiesterase Type 4 Inhibition in CNS Diseases.
    Blokland A; Heckman P; Vanmierlo T; Schreiber R; Paes D; Prickaerts J
    Trends Pharmacol Sci; 2019 Dec; 40(12):971-985. PubMed ID: 31704172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.
    Houslay MD; Adams DR
    Biochem J; 2003 Feb; 370(Pt 1):1-18. PubMed ID: 12444918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK.
    Li X; Vadrevu S; Dunlop A; Day J; Advant N; Troeger J; Klussmann E; Jaffrey E; Hay RT; Adams DR; Houslay MD; Baillie GS
    Biochem J; 2010 Apr; 428(1):55-65. PubMed ID: 20196770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement.
    Wei X; Yu G; Shen H; Luo Y; Shang T; Shen R; Xi M; Sun H
    Bioorg Chem; 2023 Jan; 130():106278. PubMed ID: 36413930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PDE4 inhibitors for disease therapy: advances and future perspective.
    Du B; Luo M; Ren C; Zhang J
    Future Med Chem; 2023 Jul; 15(13):1185-1207. PubMed ID: 37470147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors.
    Paes D; Schepers M; Rombaut B; van den Hove D; Vanmierlo T; Prickaerts J
    Pharmacol Rev; 2021 Jul; 73(3):1016-1049. PubMed ID: 34233947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4.
    Bourtchouladze R; Lidge R; Catapano R; Stanley J; Gossweiler S; Romashko D; Scott R; Tully T
    Proc Natl Acad Sci U S A; 2003 Sep; 100(18):10518-22. PubMed ID: 12930888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges.
    Renau TE
    Curr Opin Investig Drugs; 2004 Jan; 5(1):34-9. PubMed ID: 14983971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
    Pullamsetti SS; Banat GA; Schmall A; Szibor M; Pomagruk D; Hänze J; Kolosionek E; Wilhelm J; Braun T; Grimminger F; Seeger W; Schermuly RT; Savai R
    Oncogene; 2013 Feb; 32(9):1121-34. PubMed ID: 22525277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy.
    Wang L; Burmeister BT; Johnson KR; Baillie GS; Karginov AV; Skidgel RA; O'Bryan JP; Carnegie GK
    Cell Signal; 2015 May; 27(5):908-22. PubMed ID: 25683917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism.
    Zhang HT; Crissman AM; Dorairaj NR; Chandler LJ; O'Donnell JM
    Neuropsychopharmacology; 2000 Aug; 23(2):198-204. PubMed ID: 10882846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice.
    Guo J; Lin P; Zhao X; Zhang J; Wei X; Wang Q; Wang C
    Neuroscience; 2014 Mar; 263():1-14. PubMed ID: 24434771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphodiesterase-4 modulation as a potential therapeutic for cognitive loss in pathological and non-pathological aging: possibilities and pitfalls.
    Hansen RT; Zhang HT
    Curr Pharm Des; 2015; 21(3):291-302. PubMed ID: 25159075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the Development of Phosphodiesterase-4 Inhibitors.
    Peng T; Qi B; He J; Ke H; Shi J
    J Med Chem; 2020 Oct; 63(19):10594-10617. PubMed ID: 32255344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.
    Zhang HT; Huang Y; Mishler K; Roerig SC; O'Donnell JM
    Psychopharmacology (Berl); 2005 Oct; 182(1):104-15. PubMed ID: 16010541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chlorbipram: a novel PDE4 inhibitor with improved safety as a potential antidepressant and cognitive enhancer.
    Zhang MZ; Zhou ZZ; Yuan X; Cheng YF; Bi BT; Gong MF; Chen YP; Xu JP
    Eur J Pharmacol; 2013 Dec; 721(1-3):56-63. PubMed ID: 24113523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
    Page CP; Spina D
    Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases.
    McCahill AC; Huston E; Li X; Houslay MD
    Handb Exp Pharmacol; 2008; (186):125-66. PubMed ID: 18491051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in the development of phosphodiesterase-4 inhibitors.
    Li G; He D; Cai X; Guan W; Zhang Y; Wu JQ; Yao H
    Eur J Med Chem; 2023 Mar; 250():115195. PubMed ID: 36809706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.